Dexcom (NASDAQ: DXCM) to present preliminary 2025 results and 2026 outlook at J.P. Morgan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Dexcom, Inc. filed a current report describing upcoming preliminary financial disclosures and business updates. President and CEO Jake Leach is scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, where he will discuss preliminary, unaudited results for the fourth quarter and full fiscal year 2025, as well as an initial financial outlook for fiscal 2026 and other information. These preliminary figures are subject to finalization in connection with Dexcom’s Form 10-K for the year ended December 31, 2025.
The report states that the presentation, together with two related press releases dated January 12, 2026 and January 7, 2026, includes forward-looking statements about revenue, margin guidance and strategic opportunities, which are subject to risks and uncertainties. The press releases are furnished as exhibits and are not deemed filed for liability purposes under the Exchange Act.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 7, 2026
(Exact Name of the Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
(858 ) 200-0200
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||||||||||||||
Emerging growth company | ||||||||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | |||||||||||||
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
In connection with remarks to be made at the J.P. Morgan 44th Annual Healthcare Conference on Monday, January 12, 2026, beginning at 10:30 a.m. (Eastern Time), DexCom, Inc. (“Dexcom”) President and Chief Executive Officer, Jake Leach, will report preliminary, unaudited financial results for the fourth quarter of 2025 and fiscal year 2025, initial financial outlook for fiscal year 2026, and certain other information.
The fourth quarter and fiscal year 2025 preliminary unaudited financial results contained in Mr. Leach’s presentation, the press release and this Current Report on Form 8-K are subject to finalization in connection with the preparation of Dexcom’s Annual Report on Form 10-K for the twelve months ended December 31, 2025. This Current Report on Form 8-K and the press release contain, and Mr. Leach’s presentation on January 12, 2026 will contain, forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s preliminary, unaudited revenue for the fourth quarter of and the full fiscal year 2025, including growth rates; total revenue guidance for fiscal 2026; Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for fiscal 2025 and 2026, including expected growth rates; and potential strategic and business opportunities. All forward-looking statements included in Mr. Leach’s presentation, the press release and in this Current Report on Form 8-K are made as of the date published, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and therefore are subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. Should one or more of these risks or uncertainties materialize, or should any of Dexcom’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.
In connection with Mr. Leach’s presentation, on January 12, 2026, Dexcom issued a press release announcing preliminary, unaudited results for the fourth quarter of 2025 and fiscal year 2025, initial financial outlook for fiscal year 2026, and certain other information, which is attached here as Exhibit 99.1.
Additionally, on January 7, 2026, Dexcom issued a press release providing a business update, which is attached here as Exhibit 99.2.
The information in this Item 2.02, including Exhibits 99.1 and 99.2 hereto, is furnished shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
| Number | Description | |||||||
| 99.1 | Press release dated January 12, 2026 | |||||||
| 99.2 | Press release dated January 7, 2026 | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DEXCOM, INC. | ||||||||
| By: | /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | |||||||
Date: | January 12, 2026 | |||||||
FAQ
What did Dexcom (DXCM) disclose in this 8-K filing?
Dexcom reported that its CEO will present preliminary, unaudited financial results for Q4 2025 and fiscal 2025, an initial outlook for fiscal 2026, and other information at the J.P. Morgan 44th Annual Healthcare Conference.
Are Dexcom’s Q4 2025 and fiscal 2025 results in this filing final?
No. The filing states the Q4 2025 and fiscal 2025 figures are preliminary and unaudited and remain subject to finalization in connection with Dexcom’s Form 10-K for the year ended December 31, 2025.
What future guidance does Dexcom (DXCM) reference in this report?
Dexcom refers to total revenue guidance for fiscal 2026 and Non-GAAP gross profit margin and operating margin guidance for fiscal 2025 and 2026, as discussed in the CEO’s presentation and the accompanying press release.
How does Dexcom describe the forward-looking statements in this 8-K?
Dexcom notes that statements about preliminary revenue, growth rates, guidance and strategic opportunities are forward-looking, subject to various risks and uncertainties, and could differ materially from actual results.
What exhibits are attached to Dexcom’s 8-K filing?
Exhibit 99.1 is a press release dated January 12, 2026, and Exhibit 99.2 is a press release dated January 7, 2026. Exhibit 104 is the cover page interactive data file formatted as Inline XBRL.
Are Dexcom’s press releases in this 8-K considered filed with the SEC?
The filing states that the information in Item 2.02, including Exhibits 99.1 and 99.2, is furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings unless specifically stated.